Delving into the Latest Updates on [18F]JNJ-64511070 with Synapse

Overview

Basic Info

Drug Type

Chemical drugs, Diagnostic radiopharmaceuticals

Synonyms

Target-

Action-

Mechanism-

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization

Janssen Global Services LLC

Active Organization-

Inactive Organization

Janssen Research & Development LLC

License Organization

Janssen Pharmaceuticals, Inc.Enigma Medical, Inc.

Drug Highest PhaseDiscontinuedPhase 1

First Approval Date-

Regulation-

Login to view timeline

The purpose of this study is to measure the blocking of [18F]JNJ-64511070 binding in the brain at the time after administration of a drug when the maximum plasma concentration is reached; when the rate of absorption equals the rate of elimination (tmax) of JNJ-64140284 and determine the exposure/receptor interaction of JNJ-64140284 in healthy male participants following single oral dose administration of JNJ-64140284.

Start Date17 Oct 2018

Sponsor / Collaborator

Janssen Research & Development LLC

NCT03270579

/ CompletedPhase 1

An Open-Label Study to Investigate the Regional Brain Kinetics of the Positron Emission Tomography Ligand [18F]JNJ-64511070

The main purpose of the study is to measure the whole-body distribution and radiation dosimetry of [18F]JNJ-64511070 in healthy male participants by positron emission tomography (PET) (Part A); and to measure the uptake, binding, distribution, and washout of [18F]JNJ-64511070 in the brain of healthy male participants by PET and to model tissue specific kinetics of [18F]JNJ-64511070 with the appropriate arterial input function (IF) (Part B).

Start Date12 Sep 2017

Sponsor / Collaborator

Janssen Research & Development LLC

100 Clinical Results associated with [18F]JNJ-64511070

Login to view more data

100 Translational Medicine associated with [18F]JNJ-64511070

Login to view more data

100 Patents (Medical) associated with [18F]JNJ-64511070

Login to view more data

100 Deals associated with [18F]JNJ-64511070

Login to view more data